Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: Experience in 2 Canadian provinces

Newfoundland Colorectal Cancer Registry, Department of Medicine, Memorial University of Newfoundland, St. John's, NL.
Canadian journal of surgery. Journal canadien de chirurgie (Impact Factor: 1.51). 05/2009; 52(2):92-7.
Source: PubMed


Clinical practice guidelines (CPGs) for the adjuvant treatment of colorectal cancer were published by the National Institutes of Health in 1991. The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk stage II colon cancer. We evaluated differences in concordance with guidelines in the treatment of patients with stage I-III colon cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.
We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had stage I-III colon cancer. The primary outcome was concordance with guidelines for adjuvant treatment. We evaluated factors affecting the use of chemotherapy in patients with stage II disease.
No patients received adjuvant therapy for stage I disease. Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for stage III colon cancer. Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for stage II disease. Eighteen of 41 patients (44%) in Newfoundland and Labrador and 30 of 53 patients (57%) in Ontario with high-risk features received adjuvant treatment, which was significantly higher than patients without high-risk features. There was a strong trend toward using chemotherapy in patients with stage II disease who were 50 years or younger, independent of high-risk status.
Concordance with CPGs for adjuvant chemotherapy in patients with stage II colon cancer was not optimal. This may reflect selection bias among referring surgeons, a paucity of level-I evidence and the belief that other factors such as age may play a role in predicting outcome.


Available from: Elizabeth Dicks, Nov 20, 2014
  • Source
    • "First, clinical studies of equal-access health care systems within the US have consistently observed similar chemotherapy and survival rates among AAs and NHWAs with colon cancer [11-14]. Second, colon cancer chemotherapy rates seem to be much higher in Canada than in the US [15,16]. Third, recent population-based studies of colon cancer care in California and Ontario suggested that people of color, including black people of various ethnic backgrounds, with colon cancer are much better served in California [16-18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite evidence of chemotherapy's ability to cure or comfort those with colon cancer, nearly half of such Americans do not receive it. African Americans (AA) seem particularly disadvantaged. An ethnicity by poverty by health insurance interaction was hypothesized such that the multiplicative disadvantage of being extremely poor and inadequately insured is worse for AAs than for non-Hispanic white Americans (NHWA). California registry data were analyzed for 459 AAs and 3,001 NHWAs diagnosed with stage II to IV colon cancer between 1996 and 2000 and followed until 2011. Socioeconomic data from the 2000 census categorized neighborhoods: extremely poor (>= 30% of households poor), middle (5-29% poor) and low poverty (< 5% poor). Participants were randomly selected from these poverty strata. Primary health insurers were Medicaid, Medicare, private or none. Chemotherapy rates were age and stage-adjusted and comparisons used standardized rate ratios (RR). Logistic and Cox regressions, respectively, modeled chemotherapy receipt and long term survival. A significant 3-way ethnicity by poverty by health insurance interaction effect on chemotherapy receipt was observed. Among those who did not live in extremely poor neighborhoods and were adequately insured privately or by Medicare, chemotherapy rates did not differ significantly between AAs (37.7%) and NHWAs (39.5%). Among those who lived in extremely poor neighborhoods and were inadequately insured by Medicaid or uninsured, AAs (14.6%) were nearly 60% less likely to receive chemotherapy than were NHWAs (25.5%, RR = 0.41). When the 3-way interaction effect as well as the main effects of poverty, health insurance and chemotherapy was accounted for, survival rates of AAs and NHWAs were the same. The multiplicative barrier to colon cancer care that results from being extremely poor and inadequately insured is worse for AAs than it is for NHWAs. AAs are more prevalently poor, inadequately insured, and have fewer assets so they are probably less able to absorb the indirect and direct, but uncovered, costs of colon cancer care. Policy makers ought to be cognizant of these factors as they implement the Affordable Care Act and consider future health care reforms.
    BMC Health Services Research 03/2014; 14(1):133. DOI:10.1186/1472-6963-14-133 · 1.71 Impact Factor
  • Source
    • "Clinical practice guidelines are an important tool for integration of evidence-based care into daily practice, yet physician compliance with guidelines is poor (Austin, Tu, Ko, & Alter, 2008). Although some studies have shown improvements in practice consistent with guidelines over the course of 5 to 15 years (Van Dyke et al., 2009; Wirtzfeld et al., 2009), others have suggested that substantial impacts on practice may rely on linking practice guidelines to reimbursement (Patrick & Hutchinson, 2009). In BC, MMT practice guidelines are supported by unique levers, including the requirement for a specific authorization to prescribe mandatory training sponsored by the College of Physicians and Surgeons and a system of peer assessment for compliance with guidelines (Payte, 1995). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aspects of methadone maintenance treatment (MMT) delivery, particularly daily dosing practices, are associated with longer retention in treatment. Our objective was to identify trends in compliance to MMT dosing guidelines at the population level in British Columbia, Canada, from 1996 to 2006. Analysis of a provincial drug dispensation database identified 31,724 MMT episodes initiated during the study period. The number of patients in treatment increased from 2,827 in 1996 to 9,601 in 2006. Long-term retention (>36 months) was achieved in 20%-25% of all episodes. Compliance to minimally effective dose guidelines, which is independently associated with retention, fell from 2001 to 2006. Accordingly, this decline was mirrored by 12-month retention figures, which fell from 45.9% in 2001 to 40.5% in 2005. Our evaluation has both highlighted the successes of the British Columbia Methadone program and identified aspects that may be improved to ensure safety and maximize the benefits of MMT.
    Journal of substance abuse treatment 04/2010; 39(1):22-31. DOI:10.1016/j.jsat.2010.03.008 · 2.90 Impact Factor
  • Source

Show more